Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Griesinger

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
The Lancet. Oncology|October 26, 2010
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trialEckhard Thiel, Agnieszka Korfel, Peter Martus, et al.
Therapeutic Advances in Medical Oncology|June 9, 2021
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancerMartin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, et al.
Clinical Lung Cancer|June 29, 2026
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet StudyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
The European Respiratory Journal|September 30, 2022
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registryMartin Metzenmacher, Frank Griesinger, Horst-Dieter Hummel, et al.
Lung Cancer (Amsterdam, Netherlands)|August 8, 2025
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet studyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) ImmunotherapyMarcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2025
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trialAnne-Marie C Dingemans, Konstantinos Syrigos, Lorenzo Livi, et al.
The Journal of Clinical Investigation|August 19, 2007
A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemiaUlrich Steidl, Christian Steidl, Alexander Ebralidze, et al.
Lung Cancer (Amsterdam, Netherlands)|February 21, 2021
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Martin Sebastian, Wilfried E E Eberhardt, Petra Hoffknecht, et al.
British Journal of Haematology|May 11, 2022
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysisJesko Momotow, Ina Bühnen, Karolin Trautmann-Grill, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|October 26, 2010
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trialEckhard Thiel, Agnieszka Korfel, Peter Martus, et al.
Therapeutic Advances in Medical Oncology|June 9, 2021
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancerMartin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, et al.
Clinical Lung Cancer|June 29, 2026
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet StudyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
The European Respiratory Journal|September 30, 2022
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registryMartin Metzenmacher, Frank Griesinger, Horst-Dieter Hummel, et al.
Lung Cancer (Amsterdam, Netherlands)|August 8, 2025
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet studyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) ImmunotherapyMarcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2025
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trialAnne-Marie C Dingemans, Konstantinos Syrigos, Lorenzo Livi, et al.
The Journal of Clinical Investigation|August 19, 2007
A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemiaUlrich Steidl, Christian Steidl, Alexander Ebralidze, et al.
Lung Cancer (Amsterdam, Netherlands)|February 21, 2021
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Martin Sebastian, Wilfried E E Eberhardt, Petra Hoffknecht, et al.
British Journal of Haematology|May 11, 2022
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysisJesko Momotow, Ina Bühnen, Karolin Trautmann-Grill, et al.
Pageof 16